Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis

Interferon‐α2 reduces elevated blood cell counts and splenomegaly in patients with myeloproliferative neoplasms (MPN) and may restore polyclonal hematopoiesis. Its use is limited by inflammation‐mediated toxicity, leading to treatment discontinuation in 10‐30% of patients. Ruxolitinib, a potent anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Mikkelsen, Stine Ulrik, Kjær, Lasse, Bjørn, Mads Emil, Knudsen, Trine Alma, Sørensen, Anders Lindholm, Andersen, Christen Bertel Lykkegaard, Bjerrum, Ole Weis, Brochmann, Nana, Fassi, Daniel El, Kruse, Torben A., Larsen, Thomas Stauffer, Mourits‐Andersen, Hans Torben, Nielsen, Claus Henrik, Pallisgaard, Niels, Thomassen, Mads, Skov, Vibe, Hasselbalch, Hans Carl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089176/
https://www.ncbi.nlm.nih.gov/pubmed/29932310
http://dx.doi.org/10.1002/cam4.1619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089176/
https://www.ncbi.nlm.nih.gov/pubmed/29932310
http://dx.doi.org/10.1002/cam4.1619

Ejemplares similares